CoChat

Inhibition of sialidase activity as a therapeutic approach

Open access
Glanz, Victor Yu, Myasoedova, Veronika A, Grechko, Andrey V, Orekhov, Alexander N · 2018 · Drug Design Development and Therapy

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

The demand for novel anti-influenza drugs persists, which is highlighted by the recent pandemics of influenza affecting thousands of people across the globe. One of the approaches to block the virus spreading is inhibiting viral sialidase (neuraminidase). This enzyme cleaves the sialic acid link between the newly formed virions and the host cell surface liberating the virions from the cell and maintaining the cycle of infection. Viral neuraminidases appear therefore as attractive therapeutic targets for preventing further spread of influenza infection. Compared to ion channel blockers that were the first approved anti-influenza drugs, neuraminidase inhibitors are well tolerated and target both influenza A and B viruses. Moreover, neuraminidase/sialidase inhibitors may be useful for managing some other human pathologies, such as cancer. In this review, we discuss the available knowledge on neuraminidase or sialidase inhibitors, their design, clinical application, and the current challenges.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s176220

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Simplified presentation of the influenza virus life cycle. Notes: Virions attach to host cells via interaction with surface receptors containing sialic acid residues in the glycoconjugate parts. Virions are then internalized by the cell through endocytosis. After uncoating of the virion, its genetic material is release into the cell and replicated by the RNA polymerase. New viral RNA (ribonucleoprotein) and viral proteins synthesized by the host cell assemble at the cell surface into new virions. After budding, virions need to be detached from the host cell by viral neuraminidase. This step is the target of anti-influenza neuraminidase inhibitors used in clinical practice.
Figure 1 Simplified presentation of the influenza virus life cycle. Notes: Virions attach to host cells via interaction with surface receptors containing sialic acid residues in the glycoconjugate parts. Virions are then internalized by the cell through endocytosis. After uncoating of the virion, its genetic material is release into the cell and replicated by the RNA polymerase. New viral RNA (ribonucleoprotein) and viral proteins synthesized by the host cell assemble at the cell surface into new virions. After budding, virions need to be detached from the host cell by viral neuraminidase. This step is the target of anti-influenza neuraminidase inhibitors used in clinical practice.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 59

Metadata

Authors
Glanz, V. Y., Myasoedova, V. A., Grechko, A. V., & Orekhov, A. N.
Affiliations
  • Voronezh State University (RU)
  • Research Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences (RU)
  • V.A. Negovsky Scientific Research Institute of General Reanimatology (RU)
Corresponding author
Orekhov, Alexander N
Venue
Drug Design Development and Therapy
Published
2018-10
Volume
Volume 12
Pages
3431-3437
ISSN
1177-8881 (ISSN-L)
OpenAlex
W2896331548
Cited by
59
References
48
Citations by year
2026: 1 · 2025: 12 · 2024: 11 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 12 · 2019: 4 · 2018: 1
FWCI
0.89
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
Russian Science Foundation (18-15-00254)
Topics
  • Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
  • Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
Keywords
neuraminidase inhibitors, sialidase inhibitors, influenza virus, anti-influenza drugs, sialic acid, viral shedding, influenza A and B, drug design, cancer therapy, clinical application
MeSH terms
Animals, Antiviral Agents, Enzyme Inhibitors, Humans, Influenza, Human, Neuraminidase, Influenza A virus, Influenza B virus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.